skip to main content

Analysis Of Clerodendrum inerme Plant Compounds as Anti Diabetes Mellitus Through Network Pharmacology Approach

1Faculty of Health Science, Universitas Muhammadiyah Malang, Indonesia

2Department Pharmacy, Universitas Muhammadiyah Malang, Indonesia

Received: 8 Mar 2023; Revised: 27 Dec 2023; Accepted: 31 Oct 2023; Available online: 31 Dec 2023; Published: 31 Dec 2023.
Open Access Copyright (c) 2023 Journal of Biomedicine and Translational Research
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:

Background:  Diabetes mellitus prevalence in Indonesia has surged. In 2021, an estimated 19.5 million people had diabetes, with a 10.6% age-adjusted prevalence. Projections indicate around 9.5 million cases by 2024. Diabetes medications, such as metformin, are commonly used, although these medications have adverse effects. A common choice for chronic diseases like DM is the use of natural medications. A plant known as Clerodendrum inerme has the potential to alleviate diabetes, but little is known about its molecular mechanisms

Objective: The purpose of this study was to explore the content of Clerodendrum inerme plant compounds and their potential for cases of Diabetes Mellitus.

Methods: The KNApSAcK was used to conduct an analysis of plant parts of Clerodendrum inerme to seek out chemicals present in plants. A screening was done to find compounds by estimating Absorption, Distribution, Metabolism, and Excretion (ADME) parameters using the canonical Simplified molecular-input line-entry system (SMILES) on the SwissADME. On the SwissTargetPrediction tool, predictions of target proteins from compounds that pass screening are connected to various probable proteins. utilising the String-db  to show the network between target proteins and associated diseases

Results: The Clerodendrum inerme consist of 24 different compound. The 24 compounds were screened, and the results showed that 4 of them, specifically (Z)-3-Hexenyl beta-D-glucopyranoside, Rhodioloside, Sammangaoside B, and Clerodermic acid, had the potential to be developed into therapeutic agent. The compound are then analysed in order to find the protein target associated with diabetes mellitus and predict its networks. The findings indicate that multiple target proteins, including GSK3B, PPARG, DPP4, and STAT3, are connected to diabetes mellitus.

Conclusion: It has been shown that (Z)-3-Hexenyl beta-D-glucopyranoside, or clerodermic acid, is able to attach to the proteins GSK3B, PPARG, DPP4, and STAT3, which are all linked to diabetes mellitus.

Fulltext View|Download
Keywords: Clerodendrum inerme; Diabetes Mellitus; molecular mechanism; potential; therapeutic

Article Metrics:

  1. IDF. Diabetes facts and figures show the growing global burden for individuals, families, and countries. 2023. p. 1–6
  2. Monobe K, Noso S, Babaya N, Hiromine Y, Taketomo Y, Niwano F, et al. Clinical and genetic determinants of urinary glucose excretion in patients with diabetes mellitus. J Diabetes Investig. 2021 May;12(5):728–37
  3. Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021 Aug;17(8):484–95
  4. Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, Schmidt HHHW. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci. 2022 Feb;43(2):136–50
  5. Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res. 2020;2020
  6. Szmuilowicz ED, Josefson JL, Metzger BE. Gestational Diabetes Mellitus. Endocrinol Metab Clin North Am. 2019 Sep;48(3):479–93
  7. Yosmar R, Almasdy D, Rahma F. Survei Risiko Penyakit Diabetes Melitus Terhadap Masyarakat Kota Padang. J Sains Farm Klin. 2018 Aug;5(2):134–41
  8. Liu J, Liu J, Tong X, Peng W, Wei S, Sun T, et al. Network Pharmacology Prediction and Molecular Docking-Based Strategy to Discover the Potential Pharmacological Mechanism of Huai Hua San Against Ulcerative Colitis. Drug Des Devel Ther. 2021;15:3255–76
  9. Wu N, Yuan T, Yin Z, Yuan X, Sun J, Wu Z, et al. Network Pharmacology and Molecular Docking Study of the Chinese Miao Medicine Sidaxue in the Treatment of Rheumatoid Arthritis. Drug Des Devel Ther. 2022;16:435–66
  10. Kar P, Dutta S, Chakraborty AK, Roy A, Sen S, Kumar A, et al. The antioxidant rich active principles of Clerodendrum sp. controls haloalkane xenobiotic induced hepatic damage in murine model. Saudi J Biol Sci. 2019 Nov;26(7):1539–47
  11. Nakamura Y, Mochamad Afendi F, Kawsar Parvin A, Ono N, Tanaka K, Hirai Morita A, et al. KNApSAcK metabolite activity database for retrieving the relationships between metabolites and biological activities. Plant Cell Physiol. 2014;55(1):1–9
  12. Kim S, Thiessen PA, Cheng T, Yu B, Shoemaker BA, Wang J, et al. Literature information in PubChem: Associations between PubChem records and scientific articles. J Cheminform. 2016 Jun 10;8(1)
  13. Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(October 2016):1–13
  14. Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: A web server for target prediction of bioactive small molecules. Nucleic Acids Res. 2014 Jul 1;42(W1)
  15. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021 Jan;49(D1):D605–12
  16. Ono K. Introduction to Biological Network Analysis and Visualization with Cytoscape. 2016
  17. Nogara PA, Saraiva RDA, Caeran Bueno D, Lissner LJ, Lenz Dalla Corte C, Braga MM, et al. Virtual screening of acetylcholinesterase inhibitors using the Lipinski’s rule of five and ZINC databank. Biomed Res Int. 2015 Jan;2015
  18. Daina A, Zoete V. A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem. 2016;1117–21
  19. An WF, Germain AR, Bishop JA, Nag PP, Metkar S, Ketterman J, et al. Discovery of Potent and Highly Selective Inhibitors of GSK3b. Probe Reports from NIH Mol Libr Progr. 2010;
  20. Zhu YR, Jiang XX, Ye P, Wang ZM, Zheng Y, Liu Z, et al. Knockout of AKAP150 improves impaired BK channel-mediated vascular dysfunction through the Akt/GSK3β signalling pathway in diabetes mellitus. J Cell Mol Med. 2020 Apr;24(8):4716–25
  21. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, et al. Isolation of the Human Peroxisome Proliferator Activated Receptor Gamma cDNA: Expression in Hematopoietic Cells and Chromosomal Mapping. Gene Expr. 1995;4(4–5):281
  22. Sarhangi N, Sharifi F, Hashemian L, Hassani Doabsari M, Heshmatzad K, Rahbaran M, et al. PPARG (Pro12Ala) genetic variant and risk of T2DM: a systematic review and meta-analysis. Sci Rep. 2020 Dec;10(1)
  23. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19(5):557–66
  24. Zhang Y, Lin C, Chen R, Luo L, Huang J, Liu H, et al. Association analysis of SOCS3, JAK2 and STAT3 gene polymorphisms and genetic susceptibility to type 2 diabetes mellitus in Chinese population. Diabetol Metab Syndr. 2022 Dec;14(1)
  25. Gurzov EN, Stanley WJ, Pappas EG, Thomas HE, Gough DJ. The JAK/STAT pathway in obesity and diabetes. FEBS J. 2016 Aug;283(16):3002–15
  26. Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in Cardiometabolic Disease. Circ Res. 2015 Apr;116(8):1491–504

Last update:

No citation recorded.

Last update:

No citation recorded.